Alexandre I.
- Country
- France
- Department
- Urologie
Research Overview
- Phase III Randomized Controlled Trial of Adjuvant Durvalumab and Tremelimumab in Resected High-Risk Renal Cell Carcinoma
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Saruparib (AZD5305) with New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
- TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer
Data & Insights
Has run more than one trial at 15 of 131 partner sites.
Specializations
Urological Oncology
This investigator specializes in advanced therapeutic approaches for metastatic prostate cancer, with particular emphasis on castration-sensitive disease states. Their research encompasses novel treatment combinations, including targeted therapies for patients with specific genetic profiles.
- Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Genetic Mutation Analysis
- Hormonal Therapy Optimization
Their work focuses on evaluating progression-free survival outcomes in prostate cancer patients receiving various therapeutic combinations.
Kidney Cancer Research
The investigator conducts significant research in renal cell carcinoma, particularly focusing on adjuvant therapy approaches for patients following surgical intervention. Their work explores immunotherapy-based treatment strategies for high-risk populations.
- Post-Surgical Cancer Recurrence Prevention
- Immunotherapy Applications
- Risk-Stratified Treatment Approaches
Their research evaluates survival outcomes and recurrence patterns in kidney cancer patients under various therapeutic interventions.
Therapeutic Innovation
The investigator explores combination therapy approaches in urological cancers, incorporating both established and emerging treatment modalities. Their work includes evaluation of immunological agents and their impact on patient outcomes.
- Novel Drug Combinations
- Treatment Response Assessment
- Patient Monitoring Protocols
Their research encompasses both targeted therapies and immunotherapeutic approaches in urological malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.